Illegal Sale of E-Cigarettes in Brazil: Man Arrested with 33 Devices

Regulations by 2FIRSTS.ai
Nov.28.2023
Illegal Sale of E-Cigarettes in Brazil: Man Arrested with 33 Devices
Brazilian police seize 33 e-cigarettes and 510 packages from a 52-year-old man's residence in Brasilia for illegal sales.

According to a report by Dourados News, the Brazilian police conducted a search at the residence of a 52-year-old man in Brasília on the morning of the 27th, based on a court order. During the search, they seized e-cigarettes that he had been selling in nightclubs.

 

A man has been found in possession of a total of 33 e-cigarettes, along with an additional 510 packaging for e-cigarettes.

 

The local authorities have stated that the illicit products sold by the man have been completely confiscated and he will face legal consequences.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Company | Itsuwa Technology to Establish French Subsidiary to Boost Overseas Footprint; 2024 Net Profit Down 194.47% YoY
Company | Itsuwa Technology to Establish French Subsidiary to Boost Overseas Footprint; 2024 Net Profit Down 194.47% YoY
Itsuwa Technology announced that it plans to establish a wholly owned subsidiary in Paris, France—ITSUWA FRANCE—with a registered capital of €10,000, to engage in promotion, marketing activities, and brand management. In 2024, the company’s revenue fell 12.59% to RMB 283 million, and it recorded a net loss of RMB 19.66 million. The investment aims to strengthen overseas presence and enhance brand and market responsiveness.
Sep.12 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Global Tobacco Control Policy Debate: Medical Experts Call for Science-Based Approach, Promoting Harm Reduction Over Total Bans
Global Tobacco Control Policy Debate: Medical Experts Call for Science-Based Approach, Promoting Harm Reduction Over Total Bans
Health professionals worldwide are urging a shift from abstinence-only tobacco policies toward evidence-based harm reduction. Despite bans, smoking remains prevalent in countries like India, while prohibition fuels black markets in Europe and misinformation among doctors in the U.S. Many argue that regulated alternatives could save lives where cessation fails.
Sep.09
Philip Morris Korea Extends IQOS ILUMA i Warranty to 18 Months, Says Move Will Boost Smoke-Free Product Growth
Philip Morris Korea Extends IQOS ILUMA i Warranty to 18 Months, Says Move Will Boost Smoke-Free Product Growth
Philip Morris International’s Korea unit has extended the warranty for the “IQOS ILUMA i” heated tobacco series from 12 to 18 months, applying it retroactively to existing purchases, aiming to enhance user experience and market competitiveness.
Oct.15 by 2FIRSTS.ai
South Korea to ban vape vending machines near schools from February 15, 2026
South Korea to ban vape vending machines near schools from February 15, 2026
Starting from February 15, 2026, South Korea bans e-cigarette vending machines within 200m of schools to protect youth from nicotine products.
Oct.14 by 2FIRSTS.ai
Chill Brands and SYP Global Develop Novel Nicotine Delivery System, Expected to Launch Within 12 Months
Chill Brands and SYP Global Develop Novel Nicotine Delivery System, Expected to Launch Within 12 Months
Chill Brands Group has formed a strategic partnership with SYP Global, which is developing a heating-free nicotine delivery technology designed to reduce harmful by-products. Chill Brands will support SYP’s market entry through its distribution network, though commercial launch is expected within 12 months with no immediate revenue impact.
Sep.09